• TempraMed plans a non-brokered private placement of up to 16,000,000 units at CAD 0.50 each, raising up to CAD 8 million.
• Each unit comprises one common share and one non-transferable common share purchase warrant.
• Each warrant permits the purchase of one common share at CAD 1 for 18 months following closing.
• Proceeds will fund global expansion, demand fulfillment and product development, alongside marketing and general working capital.
• Closing is expected around November 13, 2026, subject to Canadian Securities Exchange approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempramed Technologies Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610200700NEWSFILECNPR____20261020_319885_1) on October 20, 2026, and is solely responsible for the information contained therein.